

Table SI. Administration of PD-1 inhibitors.

Items	Total (n=72)	Lung cancer(n=45)	Malignant melanoma(n=12)	Others(n=15)
Sintilimab, n (%)	21 (0.3)	15 (0.3)	0 (0.0)	6 (0.4)
Pembrolizumab, n (%)	19 (0.3)	15 (0.3)	3 (0.3)	1 (0.1)
Toripalimab, n (%)	14 (0.2)	2 (0.0)	9 (0.8)	3 (0.2)
Nivolumab, n (%)	10 (0.1)	10 (0.2)	0 (0.0)	0 (0.0)
Camrelizumab, n (%)	8 (0.1)	3 (0.1)	0 (0.0)	5 (0.3)

PD-1, programmed cell death-1.